当前位置 首页 科研队伍

中科院青促会会员

段红霞  博士 副研究员  

金沙集团1862cc青年创新促进会会员 
中科院生物物理所,蛋白质与多肽药物所重点实验室

研究方向:肿瘤免疫学

电子邮件:cherryshoen@aliyun.com

电       话:010-64888503

通讯地址:北京市朝阳区大屯路15号(100101)

英文版个人网页:http://english.ibp.cas.cn/sourcedb/rck/EN_zkyqchhy/202005/t20200519_339585.html

简       历:

  2002 - 2007  武汉科技大学医学院 获医学学士学位

  2007 - 2009  华中科技大学同济医学院 获医学硕士学位

  2009 - 2013  金沙集团1862cc大学 获理学博士学位

  2013 - 2016  金沙集团1862cc 博士后

  2016 - 至今    金沙集团1862cc 副研究员

获奖及荣誉:

  2011年  金沙集团1862cc学业奖

  2015年  国际生物物理大会 Young Scientist Travel Award

社会任职:

  中国免疫学会临床免疫分会委员

研究方向:

  非可控性炎症与肿瘤恶性转化之间的内在联系一直是肿瘤研究的热点和难点。炎症微环境中的血管新生和免疫失衡是非可控性炎症的两大重要特征。我们主要围绕这两大特征进行系统的机制研究。前期发现粘附分子 CD146 是血管新生和免疫失衡的重要链接分子,靶向 CD146 可以预防和控制非可控性炎症的发生发展。我们将从肝炎-肝癌恶性转化角度出发,将分子生物学与系统生物学、临床医学融合交叉,进一步阐明 CD146 在肿瘤免疫失衡中的网络调控及机制。

承担项目情况:

  1.中国博士后科学基金面上项目一等资助(2015M570159),2015.6-2016.6,已结题,主持

  2.国家自然科学基金青年基金(81502547),2016.1-2018.12,已结题,主持

  3.国家自然科学基金重大研究计划集成项目(91529306),2016.1-2018.12,已结题,研究骨干

  4.北京市自然科学基金面上项目(7192123),2019.1-2021.12,主持

代表论著:

1. Xue B, Wang P, Yu W, Feng J, Li J, Zhao R, Yang Z*, Yan X*, Duan H*. CD146 as a promising therapeutic target for retinal and choroidal neovascularization diseases. Sci China Life Sci. 2021, Oct 29. doi: 10.1007/s11427-021-2020-0. Online ahead of print.

2. Duan H#, Jing L#, Jiang X, Ma Y, Wang D, Xiang J, Chen X, Wu Z, Yan H, Jia J, Liu Z, Feng J, Zhu M*, Yan X*. CD146 bound to LCK promotes TCR signaling and anti-tumor immune response in mice. J Clin Invest. 2021, Nov 1;131(21):e148568. doi: 10.1172/JCI148568.

3. Chen X#, Yan H#, Liu D, Xu Q, Duan H, Feng J*, Yan X*, Xie C*. Structure basis for AA98 inhibition on the activation of endothelial cells mediated by CD146. iScience. 2021, Apr 14;24(5):102417. doi:10.1016/j.isci.2021.102417. eCollection 2021 May 21

4. Hongxia Duan#*, Shuai Zhao#, Jianquan Xiang#, Chenhui Ju, Xuehui Chen, Irene Gramaglia and Xiyun Yan*. Targeting the CD146/Galectin-9 axis protects the integrity of the blood-brain barrier against experimental cerebral malaria. Cell Mol Immunol. 2021, Oct;18(10):2443-2454. doi: 10.1038/s41423-020-00582-8. Epub 2020 Nov 17.

5. DUAN Hongxia# , XIONG Chaoliang# , JING Lin# , XU Qingji , LIU Jingyu ,MA Xinran , WANG Daji , XIANG Jianquan , HE Zhiheng , FENG Jing , YAN Xiyun. Review and prospect of CD146 research, 中国科学: 生命科学. 2020, doi: 10.1360/SSV-2020-0238.

6. Daji Wang#, Hongxia Duan#, Jing Feng, Jianquan Xiang, Liqun Feng, Dan Liu, Xuehui Chen, Lin Jing, Zheng Liu, Dexi Zhang, Hongjun Hao, Xiyun Yan. Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction. (#Co-first author) Theranostics. 2020, Vol. 10, Issue 1.

7. Shuai Zhao, Hongxia Duan, Yili Yang, Xiyun Yan*, Kelong Fan*. Fenozyme Protects the Integrity of the Blood–Brain Barrier against Experimental Cerebral Malaria. Nano Lett. 2019.

8. Yongting Luo#, Hongxia Duan#, Yining Qian#, Liqun Feng, Zhenzhen Wu, Jing Feng, Dongling Yang, Zhihai Qin, Xiyun Yan. Macrophage CD146 promotes atherosclerosis by trapping macrophages in the plaques. (#Co-first author) Cell Res. 2017, Mar;27(3):352-372 

9. Duan H, Xing S, Luo Y, Feng L, Gramaglia I, Zhang Y, Lu D, Zeng Q, Fan K, Feng J, Yang D, Qin Z, Couraud PO, Romero IA, Weksler B, Yan X. Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS. Sci Rep. 2013, 3:1687.

10. Duan H, Luo Y, Hao H, Feng L, Zhang Y, Lu D, Xing S, Feng J, Yang D, Song L, Yan X. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis. Neuroscience. 2013, Apr 3;235:16-26.   

11. Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Yan H, Lu D, Ye Z, Hao J, Feng J, Yang D, Yan X. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood. 2012, Sep 13;120(11):2330-9. 

12. Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, Feng J, Yang D, Fu L, Yan X. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.Proc Natl Acad Sci U S A. 2012, Jan 24;109(4):1127-32.

13. Qian YN, Luo Y, Duan HX, Feng LQ, Bi Q, Wang YJ, Yan XY. Adhesion Molecule CD146 and its Soluble Form Correlate Well with Carotid Atherosclerosis and Plaque Instability. CNS Neurosci Ther. 2014, 20(5):438-45.

14. Shu Xing, Luo Y, Zhihua Liu, Pengcheng Bu, Hongxia Duan, Dan Liu, Ping Wang, Jing Yang, Lina Song, Jing Feng, Dongling Yang, Zhihai Qin, Xiyun Yan. Targeting endothelial CD146 attenuates colitis and prevents colitis-associated-carcinogenesis. Am J Pathol. 2014, 184:1604-16.

15. Wang P, Luo Y, Duan H, Xing S, Zhang J, Lu D, Feng J, Yang D, Song L, Yan X. MicroRNA-329 suppresses angiogenesis by targeting CD146. Mol Cell Biol. 2013, 33(18):3689-99.

16. Zeng Q, Wu Z, Duan H, Jiang X, Tu T, Lu D, Luo Y, Wang P, Song L, Feng J, Yang D, Yan X. Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice. Protein Cell, 2014, 5(6):445-56.

17. Gao Q, Chen X, Duan H, Wang Z, Feng J, Yang D, Song L, Zhou N, Yan X. FXYD6: a novel therapeutic target toward hepatocellular carcinoma. Protein Cell. 2014, Jul;5(7):532-43.

申请发明专利:

1. 阎锡蕴,罗永挺,段红霞,冯立群,卢迪,冯静,杨东玲,CD146及其抗体诊断和治疗自身免疫病等炎症性疾病的应用,专利号ZL 2011 1 0188035.9;

2. 阎锡蕴,姜天霞,罗永挺,段红霞,卢迪,杨东玲,冯静,靶向作为 VEGFR-2共受体 CD146 的功能在抗肿瘤血管新生治疗中的应用,专利号:201210223311.5;

3. 阎锡蕴,王平,罗永挺,段红霞,冯静,杨东玲,宋丽娜,CD146作为预防和/或治疗缺血性眼部疾病的药物靶点的应用,专利号:201310295008;

4. 阎锡蕴,曾启群,吴真真,卢迪,段红霞,罗永挺,杨东玲,冯静,CD146及其抗体诊断和治疗三阴性乳腺癌的应用,专利号:201110412778.X;

5. 曾小峰,阎锡蕴,张令令,李梦涛,张德玺,段红霞,罗永挺,CD146作为分子标记物在诊断、分期或预后神经精神性狼疮中的作用,专利号:201410350619.51.

(资料来源:段红霞副研究员,2021-11-08)